Aragen, a global contract research, development and manufacturing organization, has secured a $100 million investment from Quadria Capital, an Asia healthcare-focused Private Equity fund. Quadria acquires a minority stake in Aragen at an approximate valuation of $1.4 billion.

This funding will support Aragen’s strategic expansion of its capabilities and infrastructure to support growing demand for outsourcing services from innovators in the U.S. and Europe.

“We are delighted to welcome Quadria to Aragen. This investment marks a pivotal moment as we scale to meet the needs of a rapidly evolving market,” said Manni Kantipudi, CEO, Aragen Life Science. “Our expanded capabilities will allow us to support the rising demand for integrated discovery and manufacturing services, and, most importantly, help our customers accelerate their programs to market faster and more efficiently.”

Aragen aims to benefit from macro trends in the outsourcing market, with Western innovator companies increasingly seeking to diversify and secure their supply chain as a hedge against operational disruptions due to global factors. The company provides services from early discovery through to commercial manufacturing for small molecules and biologics and has seen its global clientele grow to more than 400 clients, including 15 of the top 20 pharma.

Dr. Amit Varma, Managing Partner and co-Founder of Quadria Capital, said, “The pharmaceutical outsourcing sector presents compelling growth opportunities, especially in the current environment which is driven by global supply chain reorganization. Aragen’s impressive track record, customer-centric approach, and commitment to innovation make it an ideal partner for global pharmaceutical companies. We look forward to partnering with them and supporting their next phase of growth.”